Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
20n Bio
Malvern (Greater Philadelphia region), Pennsylvania, United States20n.bio ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
20n Bio has developed a proprietary platform for the rapid discovery and optimization of cyclic peptide therapeutics. The company is leveraging this technology to build an internal pipeline and has established partnerships by licensing early-stage hits. No clinical results have been published as programs are preclinical[1][2].
- Therapeutic areas
- OncologyMetabolic Disorders
- Modalities
- Cyclic peptidesPeptide-drug conjugatesOral peptidesRadioligand therapy (peptide-based)
- Industry
- Biotech
02
Partnerships
Pharmaceutical and biotechnology companies via licensing early hits and providing customized solutions, but no specific partners named publicly[1].
Beyond the preview
Go deeper on 20n Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 20n Bio.